Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sarcopenic obesity seems to impair insulin signaling in hepatocytes, resulting in increased de novo hepatic lipogenesis and inhibited hepatic β-oxidation [141].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, although the major source of hepatocellular triglycerides are adipose tissue-derived NEFA, the rate of hepatic de novo lipogenesis is also much greater in MASLD, further contributing to intrahepatic lipid accumulation [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Remarkably, the major fraction of hepatocellular triglycerides in people with obesity and MASLD is not derived from non-esterified fatty acids (NEFA) provided by dietary lipids, but from circulating NEFA released from adipose tissue [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
In the citing paper
“In individuals with MASLD and obesity, hepatic TG is reported to derive approximately 59% from circulating FFAs, 26% from DNL, and 15% from dietary sources [67].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [67]
In the citing paper
“IHTG was composed mainly of FFAs from SAT lipolysis (∼60%) and, to a lesser extent, FFAs from DNL (∼25%) or diet (∼15%).”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [23]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794 · cited 1×
“Given previous observations of higher fed-state DNL (23) and the known stimulatory effect of insulin on fatty acid synthesis (24), we were surprised that fed-state lipogenesis assessed at 1500 in tTRL TAG did not differ from values obtained in the fasting Figure 1 Model of lipid flux through the liver.”
ResultSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · cited 2×
“Insulin resistance has been shown to be associated with dysregulation of adiposederived fatty acid flux in the fasting state (10–12), and strong evidence exists demonstrating that in NAFLD patients, insulin does not suppress adipose tissue lipolysis to the same extent that it does in healthy individuals (13).”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360 · cited 6×
“Dixon, J.B., Bhathal, P.S., and O’Brien, P.E. 2001.”
Influential
Research works printed but not linked: 6
- Donnelly, 2004, Diabetes., 56, A53
- 10.2337/diabetes.53.3.521 · DOI · Paper page
- Barrows, 2004, Diabetes., 56, A1388
- Timlin, 2004, Diabetes., 56, A338
- Baar, 2005, Am. J. Physiol., 288, E187
- Hellerstein, 1993, Am. J. Physiol., 265, E814
Cited by
Items 701–800 of 1,038
Bernsmeier, C., Weisskopf, D. M., Pflueger, M. O., Mosimann, J., Campana, B., Terracciano, L., Beglinger, C., Heim, M. H., & Cajochen, C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143293 · Cited by 93
“In humans diurnal regulation of plasma lipids has been shown [15] as well as disturbance of the diurnal pattern of de-novo lipogenesis in the liver of NAFLD patients [31].”
BackgroundWada, T., Sunaga, H., Miyata, K., Shirasaki, H., Uchiyama, Y., & Shimba, S. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.693655 · Cited by 105
“In patients with nonalcoholic fatty liver disease, 60% of liver triglyceride content is derived from free fatty acid from adipose tissue, 26% from de novo lipogenesis, and 15% from diet (36).”
Pathogenesis of alcoholic liver disease
Sugimoto, K., & Takei, Y. (2016) · Hepatology Research · doi:10.1111/hepr.12736 · Cited by 104
Overnutrition, Ectopic Lipid and the Metabolic Syndrome
Grundy, S. M. (2016) · Journal of Investigative Medicine · doi:10.1136/jim-2016-000155 · Cited by 117
PeiZhen, X., Ji, H., Ye, Y., Zhang, B., Chen, Y., Tian, J., Pin, L., Chen, L., & Du, Z. (2016) · Fish Physiology and Biochemistry · doi:10.1007/s10695-016-0283-6 · Cited by 102
Kelly, D. M., Nettleship, J. E., Akhtar, S., Muraleedharan, V., Sellers, D. J., Brooke, J. C., McLaren, D. S., Channer, K. S., & Jones, T. H. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.06.007 · Cited by 98
The influence of dietary fatty acids on liver fat content and metabolism
Hodson, L., Rosqvist, F., & Parry, S. A. (2020) · Proceedings of the Nutrition Society · doi:10.1017/s0029665119000569 · Cited by 93
“By using stable-isotope tracer methodology, they found after 5 d labelling that the relative contribution of systemic NEFA, DNL fatty acids and dietary fatty acids to IHTAG was 59, 26 and 15 %, respectively((20)).”
InfluentialSheng, D., Zhao, S., Gao, L., Zheng, H. S., Liu, W., Hou, J. Y., Jin, Y., Ye, F., Zhao, Q., Li, R., et al. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0339-2 · Cited by 107
Rossmeisl, M., Medříková, D., van Schothorst, E. M., Pavlišová, J., Kuda, O., Hensler, M., Bardová, K., Flachs, P., Staňková, B., Vecka, M., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.11.010 · Cited by 103
Kinetics of plasma triglycerides in abdominal obesity
Björnson, E., Adiels, M., Taskinen, M., & Borén, J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000375 · Cited by 106
Lee, J., Homma, T., Kurahashi, T., Kang, E. S., & Fujii, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.06.121 · Cited by 104
“While the de novo synthesis of fatty acids accounts for 26% of the hepatic triglycerides in NAFLD patients [3], a high fat-containing diet is often administered to create pathological model animals for NAFLD.”
BackgroundParlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., O'Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049152 · Cited by 97
“Since uptake of TG from the diet eventually contributes to VLDL-TG production [37,38], reduced chylomicron production may contribute to the observed effect of GLP-1 receptor agonism on hepatic VLDL production.”
BackgroundLiao, J., Xie, X., Wang, N., Wang, Y., Zhao, J., Chen, F., Qu, F., Wen, W., Miao, J., & Cui, H. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155285 · Cited by 102
Herrnberger, L., Hennig, R., Kremer, W., Hellerbrand, C., Goepferich, A., Kalbitzer, H. R., & Tamm, E. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115005 · Cited by 88
“For the synthesis of VLDL, hepatocytes require triglycerides, which derive from chylomicron remnants, from de novo lipogenesis or from albumin-bound fatty acids [48].”
BackgroundJha, P., Claudel, T., Baghdasaryan, A., Mueller, M., Halilbasic, E., Das, S. K., Lass, A., Zimmermann, R., Zechner, R., Hoefler, G., et al. (2014) · Hepatology · doi:10.1002/hep.26732 · Cited by 96
“In NAFLD patients, increased peripheral FA flux from WAT has been shown to contribute 59% to the hepatic TG content, while only 26% from de novo lipogenesis and 15% from diet.(22) Our study now demonstrates that MCD diet as a murine model increases the activities of key lipolytic enzymes such as ATGL and HSL, resultin…”
BackgroundProtective effect of alcohol consumption for fatty liver but not metabolic syndrome
Hamaguchi, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i2.156 · Cited by 95
Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease
Mirtschink, P., Jang, C., Arany, Z. P., & Krek, W. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx518 · Cited by 107
“contribution of DNL in the liver becomes more prominent in the presence of NAFLD, rising from 10% up to 26%.(82,83) Although both increased fat and sugar intake can induce NAFLD, enzymes of DNL are particularly upregulated in fructose-rich diets.”
BackgroundLuo, Z., Xu, W., Zhang, Y., Di, L., & Shan, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105088 · Cited by 104
Rao, G., Peng, X., Li, X., An, K., He, H., Fu, X., Li, S., & An, Z. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1294267 · Cited by 113
The Role of SCAP/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis
Chandrasekaran, P., & Weiskirchen, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021109 · Cited by 104
“The hallmark feature of insulin resistance and obesity states in MASLD is that the content of hepatic fatty acids derived from de novo lipogenesis contributes about 26%, in contrast to 5% in normal healthy individuals [52] Int.”
BackgroundInfluentialRosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients
Antonopoulos, S., Mikros, S., Mylonopoulou, M., Kokkoris, S., & Giannoulis, G. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.08.021 · Cited by 96
Vyas, D., Kadegowda, A. K. G., & Erdman, R. A. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2012/932928 · Cited by 104
“During hepatic steatosis about 59% of hepatic TG is derived from free FA released from the adipose tissue and 15% is derived from dietary fat [89].”
BackgroundNASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages
Bieghs, V., Rensen, P. C. N., Hofker, M. H., & Shiri‐Sverdlov, R. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.08.041 · Cited by 108
“The magnitude of post-prandial TG and oxLDL responses after oral fat load tests has been shown to correlate with the severity of the liver histopathology [34–38].”
BackgroundTricò, D., Caprio, S., Umano, G. R., Pierpont, B. M., Nouws, J., Galderisi, A., Kim, G., Mata, M. M., & Santoro, N. (2018) · Hepatology · doi:10.1002/hep.30035 · Cited by 100
“In fact, visceral adipose tissue is the main source of free fatty acids for hepatic triglycerides synthesis (~65%) (36) and is typically”
BackgroundChemoprevention of nonalcoholic fatty liver disease by dietary natural compounds
Pan, M., Lai, C., Tsai, M., & Ho, C. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300522 · Cited by 99
Zhou, B., Zhou, D., Wei, X., Zhong, R.-Y., Xu, J., & Sun, L. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.175 · Cited by 97
Food components with antifibrotic activity and implications in prevention of liver disease
Bae, M., Park, Y., & Lee, J. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.11.003 · Cited by 101
“[27] showed that ~15% of hepatic fatty acids originated from diet, ~59% from adipose tissue, and ~26% from de novo lipogenesis in NAFLD patients.”
BackgroundVetrano, E., Rinaldi, L., Mormone, A., Giorgione, C., Galiero, R., Caturano, A., Nevola, R., Marfella, R., & Sasso, F. C. (2023) · Biomedicines · doi:10.3390/biomedicines11020468 · Cited by 102
“The most evocative theory in the pathogenesis of NAFLD is the “two-shot” hypothesis [32].”
BackgroundMonounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats
Hussein, O. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i3.361 · Cited by 93
“Fifty-nine percent of fatty acids stored in the liver of NASH patients arises from serum non-esterified fatty acids (NEFA), 26% from de novo lipogenesis and 15% from the diet [ 30 ]”
BackgroundChen, K., Chen, X., Xue, H., Zhang, P., Fang, W., Chen, X., & Ling, W. (2019) · Food & Function · doi:10.1039/c8fo01236a · Cited by 94
Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
Kang, G. G., Trevaskis, N. L., Murphy, A. J., & Febbraio, M. A. (2023) · iScience · doi:10.1016/j.isci.2022.105905 · Cited by 94
“Emerging evidence has demonstrated that consumption of a high-fructose diet (HFrD) downregulates tight junction proteins (TJPs) and concomitantly increases hepatic de novo lipogenesis (DNL)—the production of new lipids from glucose and fructose by activation of the enzyme acetyl-coenzyme A (CoA) carboxylase (ACC).(24,…”
BackgroundDeterminants of VLDL-triglycerides production
Nielsen, S., & Karpe, F. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283544956 · Cited by 94
Effects of exercise training on intrahepatic lipid content in humans
Brouwers, B., Hesselink, M. K. C., Schrauwen, P., & Schrauwen-Hinderling, V. B. (2016) · Diabetologia · doi:10.1007/s00125-016-4037-x · Cited by 94
“[9] elegantly showed that during fasting conditions 60% of the hepatic TAG content in patients with NAFL originated from plasma NEFA.”
BackgroundRecent advances in nonalcholic fatty liver disease
Greenfield, V., Cheung, O., & Sanyal, A. J. (2008) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3282fbccf2 · Cited by 94
Carbone, L. J., Angus, P. W., & Yeomans, N. D. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13026 · Cited by 91
Endocrine causes of nonalcoholic fatty liver disease
Marino, L., & Jornayvaz, F. R. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i39.11053 · Cited by 101
Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection
Godos, J., Federico, A., Dallio, M., & Scazzina, F. (2017) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2016.1214239 · Cited by 92
“An estimation of the contribution suggests that approximately 60% of liver triglyceride content was derived from free fatty acid influx from adipose tissue, 26% from de novo lipogenesis, and 15% from the diet (Donnelly et al. 2005).”
BackgroundA review of non‐alcoholic fatty liver disease in non‐obese and lean individuals
Ahadi, M., Molooghi, K., Masoudifar, N., Namdar, A. B., Vossoughinia, H., & Farzanehfar, M. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15353 · Cited by 107
Matsuzaka, T., & Shimano, H. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00111.x · Cited by 104
Siddiqui, M. S., Sterling, R. K., Luketic, V. A., Puri, P., Stravitz, R. T., Bouneva, I., Boyett, S. L., Fuchs, M. A., Sargeant, C., Warnick, G. R., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.036 · Cited by 99
von Frankenberg, A. D., Marina, A., Song, X., Callahan, H. S., Kratz, M., & Utzschneider, K. M. (2017) · European Journal of Nutrition · doi:10.1007/s00394-015-1108-6 · Cited by 82
“On a balanced diet (30 % as fat and 55 % as carbohydrate), approximately 15 % of the hepatic triglyceride is derived from the diet [35].”
Treating NAFLD in OLETF Rats with Vigorous-Intensity Interval Exercise Training
LINDEN, M. A., FLETCHER, J. A., MORRIS, E. M., MEERS, G. M., LAUGHLIN, M. H., BOOTH, F. W., SOWERS, J. R., IBDAH, J. A., THYFAULT, J. P., & RECTOR, R. S. (2015) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000000430 · Cited by 92
“In addition, it is estimated that 925% of hepatic TG accumulation in patients with NAFLD can be accounted for by de novo lipogenesis (12).”
BackgroundClinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease
Paglialunga, S., & Dehn, C. A. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0321-5 · Cited by 111
“Augmented hepatic DNL rates are now considered a causal factor in the development of NAFLD [5, 20, 27].”
BackgroundLau, L. H. S., & Wong, S. H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_9 · Cited by 105
Interactions between Host PPARs and Gut Microbiota in Health and Disease
Hasan, A. U., Rahman, A., & Kobori, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020387 · Cited by 101
“Thus, the supply of lipids to the liver increases [20,85].”
BackgroundTanaka, M., Sato, A., Kishimoto, Y., Mabashi‐Asazuma, H., Kondo, K. N., & Iida, K. (2020) · Nutrients · doi:10.3390/nu12051479 · Cited by 98
“Uptake of circulating free fatty acids (FFAs) and de novo lipogenesis are major biological lipid sources for hepatocytes [7].”
BackgroundVLDL Biogenesis and Secretion: It Takes a Village
Zwol, W. H.-V., van de Sluis, B., Ginsberg, H. N., & Kuivenhoven, J. A. (2024) · Circulation Research · doi:10.1161/circresaha.123.323284 · Cited by 101
Xanthakos, S. A., Ibrahim, S. H., Adams, K. H., Kohli, R., Sathya, P., Sundaram, S. S., Vos, M. B., Dhawan, A., Caprio, S., Behling, C. A., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001368 · Cited by 102
Fraser, A., Abel, R., Lawlor, D. A., Fraser, D., & Elhayany, A. (2008) · Diabetologia · doi:10.1007/s00125-008-1049-1 · Cited by 100
“It has been estimated that dietary sources account for 15% of liver fat content [3].”
BackgroundKim, E. J., Kim, B., Seo, H. S., Lee, Y.-J., Kim, H. H., Son, H.-H., & Choi, M. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097841 · Cited by 101
“The pathogenesis of NAFLD is based on a ‘‘two-hit hypothesis’’ [7,8].”
Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Imajo, K., Yoneda, M., Kessoku, T., Ogawa, Y., Maeda, S., Sumida, Y., Hyogo, H., Eguchi, Y., Wada, K., & Nakajima, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121833 · Cited by 89
“An increase in diet-derived FA results in steatosis, diabetes, and obesity [21].”
BackgroundSeo, M. S., Kim, J. H., Kim, H. J., Chang, K. C., & Park, S. W. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.02.020 · Cited by 97
Perfield, J. W., Ortinau, L. C., Pickering, R. T., Ruebel, M. L., Meers, G. M., & Rector, R. S. (2013) · Journal of Obesity · doi:10.1155/2013/296537 · Cited by 88
The role of hepassocin in the development of non-alcoholic fatty liver disease
Wu, H.-T., Lu, F.-H., Ou, H.-Y., Su, Y.-C., Hung, H.-C., Wu, J.-S., Yang, Y.-C., Wu, C.-L., & Chang, C.-J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.004 · Cited by 92
“De novo lipogenesis is responsible for more than 30% of hepatic fat [7-8], and dietary lipid contributes ~10% of the hepatic lipid content [7].”
BackgroundLiu, B., Zhang, J., Sun, P., Yi, R., Han, X., & Zhao, X. (2019) · Biomolecules · doi:10.3390/biom9090435 · Cited by 92
“Both exercise and improved diet can reduce the risk of NAFLD [3].”
BackgroundBeyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology
Torre, S. D. (2021) · Cells · doi:10.3390/cells10092502 · Cited by 101
Videla, L. A., & Valenzuela, R. (2021) · BioFactors · doi:10.1002/biof.1797 · Cited by 97
“The accumulation of hepatic TGs involves different routes of FA supply, including dietary intake (15%), delivery from white adipose tissue lipolysis due to insulin resistance (59%), and intrahepatic synthesis (de novo lipogenesis; DNL) (26%) from dietary glucose and fructose consumption.(59) Under normal conditions, h…”
BackgroundEmerging Role of Hepatic Ketogenesis in Fatty Liver Disease
Mooli, R. G. R., & Ramakrishnan, S. K. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.946474 · Cited by 95
Phielix, E., Szendroedi, J., & Roden, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.006 · Cited by 97
Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters
Bilz, S., Samuel, V., Morino, K., Savage, D., Choi, C. S., & Shulman, G. I. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00355.2005 · Cited by 91
“After being acclimatized for 1 wk, animals were allocated to three groups of 8–10 animals: the control group (CON) remained on the standard rodent chow (9), the high-fructose group (HF) received pellets containing 60% calories from fructose (Dyets, Bethlehem, PA), and the third group received the same pelleted HF diet…”
BackgroundMethodMonsénégo, J., Mansouri, A., Akkaoui, M., Lenoir, V., Esnous, C., Fauveau, V., Tavernier, V., Girard, J., & Prip-Buus, C. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.008 · Cited by 91
Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease
Gaemers, I. C., Stallen, J., Kunne, C., Wallner, C., van Werven, J. R., Nederveen, A. J., & Lamers, W. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.01.003 · Cited by 99
Impact of Glucocorticoid Excess on Glucose Tolerance: Clinical and Preclinical Evidence
Pasieka, A., & Rafacho, A. (2016) · Metabolites · doi:10.3390/metabo6030024 · Cited by 90
“These morphological changes in the liver may be due to indirect effects of GCs stimulating lipolysis to elevate circulating FFA levels [75,76], or because of de novo lipogenesis in the liver itself from elevated glucose concentrations [74] (Figure 1).”
BackgroundHydes, T., Ravi, S., Loomba, R. S., & Gray, M. E. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0067 · Cited by 94
“1).(10) Excess FFAs are stored as triglycerides in the hepatocytes.”
BackgroundThe role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
Jennison, E., & Byrne, C. D. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0129 · Cited by 88
“In individuals with NAFLD, 26% of hepatic triglycerides are produced by de novo lipogenesis using fructose and other dietary sugars as substrates.(119) Fructose increases hepatic lipogenesis by activating several key transcription factors such as sterol response element-binding protein-1c and carbohydrate-responsive e…”
BackgroundTarantino, G., Balsano, C., Santini, S. J., Brienza, G., Clemente, I., Cosimini, B., & Sinatti, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413424 · Cited by 94
Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease
Dichtel, L. E., Córdoba‐Chacón, J., & Kineman, R. D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac088 · Cited by 99
Tanaka, N., Takahashi, S., Matsubara, T., Jiang, C., Sakamoto, W., Chanturiya, T., Teng, R., Gavrilova, O., & Gonzalez, F. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.605980 · Cited by 89
“Judging from the major contribution of FA originated from lipolysis in WAT to the development of NAFLD in humans (31), investigating the expression and function of adipose CIDEC in the patients having NAFLD and accompanying IR and diabetes might provide new information regarding the pathogenesis of these metabolic dis…”
BackgroundRamos-Roman, M. A., Sweetman, L., Valdez, M. J., & Parks, E. J. (2012) · Metabolism · doi:10.1016/j.metabol.2011.06.008 · Cited by 87
“Metabolic dysfunction can be uncovered by the challenge of food consumption [11,12].”
BackgroundSelf-citationCross-regulation of hepatic glucose metabolism via ChREBP and nuclear receptors
Poupeau, A., & Postic, C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.03.015 · Cited by 85
“Appropriate control of lipogenesis is crucial since excess fatty acid storage leads to hepatic steatosis and other related metabolic diseases [1].”
Caviglia, J. M., Gayet, C., Ota, T., Hernandez-Ono, A., Conlon, D. M., Jiang, H., Fisher, E. A., & Ginsberg, H. N. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m016931 · Cited by 87
D'souza, A. M., Beaudry, J. L., Szigiato, A. A., Trumble, S. J., Snook, L. A., Bonen, A., Giacca, A., & Riddell, M. C. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00378.2011 · Cited by 91
“(13) suggest 474 that up to 60% of lipids in the liver are from FFA spill over from central adipose depots.”
BackgroundThomsen, M. N., Skytte, M. J., Samkani, A., Carl, M. H., Weber, P., Astrup, A., Chabanova, E., Fenger, M., Frystyk, J., Hartmann, B., et al. (2022) · Diabetologia · doi:10.1007/s00125-021-05628-8 · Cited by 90
“Hyperinsulinaemia and hyperglycaemia augment hepatic DNL and contribute to liver fat accumulation and hypertriacylglycerolaemia [30], which can further elevate circulating NEFA levels through ‘spill-over’ during lipoprotein-bound triacylglycerol hydrolysis in the periphery [29].”
BackgroundPathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease
Akhtar, D. H., Iqbal, U., Vazquez‐Montesino, L. M., Dennis, B. B., & Ahmed, A. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00028 · Cited by 108
“Indirectly, insulin acts peripherally by stimulating the uptake of fatty acids into muscle and adipose tissue that are produced by lipoprotein lipase-mediated triglyceride hydrolysis.(21)”
BackgroundRecent advances on FXR-targeting therapeutics
Panzitt, K., Zollner, G., Marschall, H., & Wagner, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111678 · Cited by 94
“agonists would be favorable over currently available pan-FXR agonists in diseased conditions such as NAFLD since the major source of triglycerides in the liver is derived from free fatty acids and to a lesser extent from de-novo lipogenesis [113].”
BackgroundCui, B., Liu, S., Lin, X., Wang, J., Li, S., Wang, Q.-B., & Li, S. (2011) · Molecules · doi:10.3390/molecules16119116 · Cited by 90
“The liver regulates systemic lipid homeostasis, which is involved in the redistribution of lipoproteins, triacylglycerol for storage and utilization by peripheral tissues [22].”
BackgroundInhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice #
Zhao, H., Przybylska, M., Wu, I.-H., Zhang, J., Maniatis, P., Pacheco, J., Piepenhagen, P., Copeland, D., Arbeeny, C., Shayman, J. A., et al. (2009) · Hepatology · doi:10.1002/hep.22970 · Cited by 88
Pickens, M. K., Yan, J. S., Ng, R. K., Ogata, H., Grenert, J. P., Beysen, C., Turner, S. M., & Maher, J. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m900022-jlr200 · Cited by 90
Larter, C. Z., Yeh, M. M., Van Rooyen, D. M., Brooling, J., Ghatora, K., & Farrell, G. C. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06939.x · Cited by 89
Sphingolipid metabolism in non-alcoholic fatty liver diseases
Régnier, M., Polizzi, A., Guillou, H., & Loiseau, N. (2018) · Biochimie · doi:10.1016/j.biochi.2018.07.021 · Cited by 95
Tao, W., Sun, W., Liu, L., Wang, G., Xiao, Z., Pei, X., & Wang, M. (2019) · Marine Drugs · doi:10.3390/md17110645 · Cited by 96
“COS did not affect the serum TG level, presumably because the serum TG level highly varied with the lipid flux through the liver, adipose tissue, and other tissues [23].”
BackgroundN-3 Polyunsaturated Fatty Acids and Inflammation in Obesity: Local Effect and Systemic Benefit
Wang, Y., & Huang, F. (2015) · BioMed Research International · doi:10.1155/2015/581469 · Cited by 81
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
Massoud, O. I., & Charlton, M. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.014 · Cited by 95
Jelenik, T., Rossmeisl, M., Kuda, O., Jilkova, Z. M., Medrikova, D., Kus, V., Hensler, M., Janovska, P., Miksik, I., Baranowski, M., et al. (2010) · Diabetes · doi:10.2337/db09-1716 · Cited by 88
“When insulin and glucose levels are high, such as during hyperinsulinemic-euglycemic clamp, wild-type mice fed n-3 LC-PUFAs exhibit improved hepatic insulin sensitivity and decreased plasma levels of NEFAs as compared with high-fat diet-fed controls.”
BackgroundInfluentialHepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease
ter Horst, K. W., Vatner, D. F., Zhang, D., Cline, G. W., Ackermans, M. T., Nederveen, A. J., Verheij, J., Demirkiran, A., van Wagensveld, B. A., Dallinga-Thie, G. M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1644 · Cited by 88
Orlicky, D. J., Libby, A. E., Bales, E. S., McMahan, R. H., Monks, J., Rosa, F. G. L., & McManaman, J. L. (2019) · The Journal of Physiology · doi:10.1113/jp277140 · Cited by 89
“Hepatic lipid accumulation in obese, insulin resistant, NAFLD patients results from both increased uptake of elevated serum fatty acids and the stimulation of de novo lipogenesis (Donnelly et al. 2005; Lambert et al. 2014).”
BackgroundRiazi, K., Raman, M., Taylor, L., Swain, M. G., & Shaheen, A. A. (2019) · Nutrients · doi:10.3390/nu11122878 · Cited by 94
“Donnelly et al. (2005) showed that in the fasting state, the contributions of peripheral NEFAs, FA biosynthesis, and dietary fats to hepatic fat content were 59% (45.1–74.3%), 26.1% (12.7–37%), and 14.9% (4.3–28%), respectively [24].”
BackgroundInfluentialPark, S. H., Seo, W., Xu, M.-J., Mackowiak, B., Lin, Y., He, Y., Fu, Y., Hwang, S., Kim, S.-J., Guan, Y., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.10.002 · Cited by 77
“In addition to de novo lipogenesis within the hepatocytes, adipose tissue lipolysis is another important source of hepatic fatty acids.(17,33) Alcohol disturbs adipose tissue functions by mediating adipocyte death, altering secretion of proinflammatory mediators, and release of FFAs.”
BackgroundMitochondrial heterogeneity in diseases
Chen, L., Zhou, M., Li, H., Liu, D., Liao, P., Yao, Z., Zhang, C., Zou, W., & Gao, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01546-w · Cited by 93
“This adaptation of mitochondrial metabolism is the central feature of NAFLD.(248,252) In addition, mice fed an HFD showed normal mitochondrial energetics but accumulated lipotoxic byproducts, including ceramides and diacylglycerols.”
BackgroundSpatial single-cell isotope tracing reveals heterogeneity of de novo fatty acid synthesis in cancer
Buglakova, E., Ekelöf, M., Schwaiger-Haber, M., Schlicker, L., Molenaar, M. R., Shahraz, M., Stuart, L., Eisenbarth, A., Hilsenstein, V., Patti, G. J., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01118-4 · Cited by 93
“%) are close to the reported rate of 30% of de novo lipogenesis in patients with non-alcoholic fatty liver disease 36 .”
BackgroundCarbohydrate intake and nonalcoholic fatty liver disease
Neuschwander-Tetri, B. A. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328361c4d1 · Cited by 89
“NAFLD [3] and is thought to play a major role in the lipid that accumulates in the liver in NAFLD [4].”
BackgroundGLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Lee, J., Hong, S.-W., Rhee, E.-J., & Lee, W.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.4.262 · Cited by 87
Larter, C. Z., Yeh, M. M., Van Rooyen, D. M., Teoh, N. C., Brooling, J., Hou, J. Y., Williams, J., Clyne, M., Nolan, C. J., & Farrell, G. C. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05996.x · Cited by 85
Galiero, R., Caturano, A., Vetrano, E., Cesaro, A., Rinaldi, L., Salvatore, T., Marfella, R., Sardu, C., Moscarella, E., Gragnano, F., et al. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203082 · Cited by 99
“The glucokinase regulator (GCKR) is another susceptibility gene for NAFLD, which encodes liver-specific glucokinase regulatory protein (GKRP) and is involved in both hepatic de novo lipogenesis and NAFLD development [52, 71].”
Flessa, C., Kyrou, I., Ansari, N. N., Kaltsas, G., Kassi, E. N., & Randeva, H. S. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30247 · Cited by 92
Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
Yin, X., Guo, X., Liu, Z., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032844 · Cited by 102
“Fatty acid synthase (FAS) catalyzes palmitic acid generation from malo- nyl-CoA and acetyl-CoA.”
BackgroundInfluentialToll-Like Receptors in Liver Disease
Petrášek, J., Csák, T., & Szabó, G. (2012) · Advances in clinical chemistry · doi:10.1016/b978-0-12-405211-6.00006-1 · Cited by 94
Moya, M., Gómez-Lechón, M. J., Castell, J. V., & Jover, R. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.01.008 · Cited by 89
Morgan, K., Uyuni, A., Nandgiri, G., Mao, L., Castaneda, L., Kathirvel, E., French, S. W., & Morgan, T. R. M. (2008) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282f9b203 · Cited by 98
Eisinger, K., Krautbauer, S., Hebel, T., Schmitz, G., Aslanidis, C., Liebisch, G., & Buechler, C. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.05.002 · Cited by 94
Metadata
- Authors
- Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Parks, Elizabeth J.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-05-02
- Volume
- 115
- Issue
- 5
- Pages
- 1343-1351
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1087172
- OpenAlex
- W1985592156
- Semantic Scholar
- ed7633369ab77ee37699d391fe0fa59627da0df8
- Cited by
- 3,604
- References
- 50
- Citations by year
- 2026: 158 · 2025: 199 · 2024: 230 · 2023: 268 · 2022: 254 · 2021: 264 · 2020: 229 · 2019: 221 · 2018: 222 · 2017: 184 · 2016: 200 · 2015: 185 · 2014: 163 · 2013: 147 · 2012: 127
- FWCI
- 44.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Minnesota
- National Institutes of Health (RR00400)
- National Institute of Diabetes and Digestive and Kidney Diseases (R03DK058286)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (PAR-98-086)
- National Center for Research Resources (M01RR000400)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- non-alcoholic fatty liver disease, hepatic triglycerides, de novo lipogenesis, free fatty acids, VLDL, stable isotope tracers, fatty acid sources, hepatic lipid accumulation, obesity, hypertriglyceridemia, hyperinsulinemia
- MeSH terms
- Adult, Fatty Acids, Fatty Liver, Female, Humans, Lipoproteins, Liver, Male, Middle Aged, Time Factors, Triglycerides, Cholesterol, VLDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.